Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of Out-of-Region Healthcare Use and Patient Experiences in Brain Disorders in Gyeongsangnam-Do : An Andersen's Behavioral Model Approach.

Journal of Korean Neurosurgical Society·2026
Same author

Trochlear Nerve Schwannoma: An Easily Missed Diagnosis.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Long-term outcomes and late complications of intracranial germinoma: Implications for follow-up policy.

Neuro-oncology advances·2026
Same author

Reversibility of cognitive and psychiatric impairments following surgical resection of frontotemporal meningiomas: a predictive factor analysis.

BMC neurology·2026
Same author

Comparative Outcomes of Consolidation Strategies After R-MVP Induction in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.

Cancer medicine·2026
Same author

Single-Fraction Stereotactic Radiosurgery for Benign Perioptic Meningiomas: A Strategy for Long-Term Tumor Control and Radiation-Induced Optic Neuropathy Avoidance With a 10-Year Follow-up.

Journal of Korean medical science·2026

Related Experiment Video

Updated: May 25, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic radiosurgery for large brain metastases.

Jung Ho Han1, Dong Gyu Kim, Chae-Yong Kim

  • 1Department of Neurosurgery, Seoul National University Bundang Hospital, Gyeonggi-do, Korea.

Progress in Neurological Surgery
|January 13, 2012
PubMed
Summary

Stereotactic radiosurgery (SRS) shows promise for large brain metastases, with many patients improving neurologically. However, the current low-dose SRS may cause adverse effects and is not effective for tumors over 26 cm³.

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: May 25, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

  • Neurosurgery
  • Radiation Oncology
  • Oncology

Background:

  • Surgical resection is the primary treatment for large brain metastases.
  • Stereotactic radiosurgery (SRS) is being explored for large brain metastases as a primary or salvage therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-dose SRS for large brain metastases.
  • To determine if SRS provides benefits in tumor volume reduction and survival for large brain metastases.

Main Methods:

  • Patients with large brain metastases received low-dose SRS (11-12 Gy).
  • Outcomes including neurological deficit recovery and adverse radiation effects were documented.

Main Results:

  • Many large brain metastases responded promptly to SRS, with over half of patients recovering neurological deficits within one month.
  • A significant portion of patients experienced adverse radiation effects.
  • SRS alone did not demonstrate benefits in tumor volume reduction or survival for brain metastases exceeding 26 cm³.

Conclusions:

  • Low-dose SRS can lead to prompt responses and neurological recovery in some patients with large brain metastases.
  • The safety of current SRS dosing for large brain metastases requires reevaluation due to observed radiation-related injuries.
  • SRS alone may not be sufficient for brain metastases larger than 26 cm³.